LENZ Therapeutics reported a quarterly loss of $1.32 per share, wider than the Zacks consensus estimate for a $1.10 loss and worse than the $0.53 loss per share a year ago. The miss versus expectations and year-over-year deterioration point to weaker near-term fundamentals. The release is likely to pressure the stock modestly, but the article contains no guidance or other catalyst.
LENZ Therapeutics reported a quarterly loss of $1.32 per share, wider than the Zacks consensus estimate for a $1.10 loss and worse than the $0.53 loss per share a year ago. The miss versus expectations and year-over-year deterioration point to weaker near-term fundamentals. The release is likely to pressure the stock modestly, but the article contains no guidance or other catalyst.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately negative
Sentiment Score
-0.35
Ticker Sentiment
